Drug-Induced Cancer

Schmähl, D

doi:10.1007/978-3-642-67861-5_8

Cited by 12 publications

(5 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiation for benign conditions in childhood, such as ringworm of the scalp or hemangiomas, has also been found to increase the risk of both benign and malignant tumors [35,45]. There are few studies that specifically address the combined role of radiation therapy and chemotherapy in SMN [ 34,38,46], In a series of 32 patients with SMN after treatment of a childhood malignancy, a radiation dose greater than 50 cGy was identified as a risk factor for SMN; after adjustment for the dose of radiation therapy, dactinomycin increased further the relative risk of bone and soft tissue sarcomas, but cyclophosphamide was found to be less carcinogenic than other alkylating agents [36].…”

Section: Discussionmentioning

confidence: 99%

Cutaneous angiosarcoma as a second malignant neoplasm after peripheral primitive neuroectodermal tumor

Coffin

Vietti

Land

et al. 1992

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Second malignant neoplasms (SMN) in late childhood or young adulthood in individuals who have been successfully treated for an initial malignancy have emerged as a late effect of therapy in survivors of childhood cancer. Although radiation therapy is frequently implicated, chemotherapy with alkylating agents and antimetabolites has also been associated with SMN. Soft tissue sarcomas are among the most frequent primary malignancies complicated by a SMN and account for a majority of nonhematolymphoid SMN. We present the clinical and pathologic findings in a patient who had a peripheral neuroepithelioma (primitive neuroectodermal tumor, PNET) of the soft tissues diagnosed at 17 years of age, was treated with high-dose irradiation and multidrug chemotherapy, and developed an angiosarcoma 14 years later. This case represents an uncommon combination of mesenchymal malignancies in a young patient with an unusually favorable clinical course following the diagnosis of PNET.

show abstract

Section: Discussionmentioning

confidence: 99%

Cutaneous angiosarcoma as a second malignant neoplasm after peripheral primitive neuroectodermal tumor

Coffin

Vietti

Land

et al. 1992

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

show abstract

“…Treatment with genotoxic cytostatics (e.g., platinum-containing antitumor compounds) generally occurs under well defined conditions with respect to the patient's diet, smoking habits and other medication. Several of these drugs have been identified as potential carcinogens, while some have been shown to induce second tumors in patients treated with chemotherapy (57). Material obtained from these people may therefore be used to study the possible relation between certain DNA adducts and human cancer induction.…”

Section: Discussionmentioning

confidence: 99%

Use of monoclonal and polyclonal antibodies against DNA adducts for the detection of DNA lesions in isolated DNA and in single cells.

Baan¹,

Zaalberg²,

Fichtinger-Schepman³

et al. 1985

Environ Health Perspect

View full text Add to dashboard Cite

Interaction of genotoxic chemicals with their intracellular target, i.e., DNA, may result in the formation of covalent adducts. Various methods have been developed to estimate exposure to genotoxic chemicals by means of molecular dosimetry of DNA adducts. Such experiments have generally been carried out with radiolabeled genotoxicants administered in vitro to cultured cells or in vivo to laboratory animals. Biomonitoring of human exposure to genotoxic chemicals requires methods to detect very small quantities of nonradioactive DNA adducts in limited amounts of sample. Attention has been devoted to the development of immunochemical techniques in which specific DNA adducts can be detected with antibodies. The level of sensitivity achieved in these experiments renders these methods applicable for human biomonitoring. When suitable antibodies are available, the immunochemical approach enables one to analyze various types of adducts separately, and to discriminate between irrelevant (e.g., quickly repairable) and relevant lesions (key lesions) with respect to biological end points such as mutation induction and cancer. Polyclonal and monoclonal antibodies were used for the detection of DNA adducts in animal and human tissue. Adducts were measured in DNA from various organs of rats treated with the liver carcinogen 2-AAF. Human exposure to genotoxic agents was studied by the measurement of DNA adducts in blood cells from patients treated with the genotoxic cytostatic cisplatin. Also, the development is described of a system to detect and quantitate DNA adducts at the single-cell level by means of immunofluorescence microscopy, which allows the analysis of small samples of human tissue with preservation of cell morphology.ImagesFIGURE 1.

show abstract

“…The carcinogenic activity of seven representative CENUs was determined after repeated iv injections to rats. , No common target organs for lesions were found for the various CENUs although the nerve and lung tissue were most commonly affected by neoplastic lesions. ,, BCNU ( 33 ) and morpholino-CNU ( 279 ) were the most carcinogenic and HECNU ( 329 ) and HECNU-MS ( 333 ) were the least carcinogenic compounds. , Long-term experiments involving ip injections in SD rats once a week for up to 52 weeks were revealing. , The BCNU-treated rats with a median survival time (MST) of 359 days, exhibited a definite dose-related local carcinogenic effect, with malignant neoplasms in the intraperitoneal cavity while the HECNU-treated rats, with a MST of 648 days, showed no such local carcinogenic effect. ,− The CENU-carbohydrate chlorozotocin ( 368 ), which has a high activity against the L1210 leukemia and no bone marrow suppression, was a very potent carcinogen in such a long-term ip inoculation schedule. , An important conclusion 112 from this work is that chronic toxicity and carcinogenicity studies can be used to distinguish between compounds which have similar anticancer activities and acute toxicities, and that these biological parameters should be determined before subjecting new active compounds to clinical trials.…”

Section: Comparative Mutagenic and Carcinogenic Propertiesmentioning

confidence: 99%

“…5,112 The BCNU-treated rats with a median survival time (MST) of 359 days, exhibited 989 a definite dose-related local carcinogenic effect, with malignant neoplasms in the intraperitoneal cavity while the HECNU-treated rats, with a MST of 648 days, showed no such local carcinogenic effect. 14,[989][990][991][992] The CENU-carbohydrate chlorozotocin (368), which has a high activity against the L1210 leukemia and no bone marrow suppression, was a very potent carcinogen in such a long-term ip inoculation schedule. 5,990 An important conclusion 112 from this work is that chronic toxicity and carcinogenicity studies can be used to distinguish between compounds which have similar anticancer activities and acute toxicities, and that these biological parameters should be determined before subjecting new active compounds to clinical trials.…”

Section: Comparative Mutagenic and Carcinogenic Propertiesmentioning

confidence: 99%